Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials

@article{Unfer2012EffectsOM,
  title={Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials},
  author={Vittorio Unfer and Gianfranco Carlomagno and Giulia Dante and Fabio Facchinetti},
  journal={Gynecological Endocrinology},
  year={2012},
  volume={28},
  pages={509 - 515}
}
Polycystic ovary syndrome (PCOS) affects 5%–10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of… 

Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials

This systematic review is the analysis of recent randomized clinical trials of inositol(s) in PCOS, in particular myo- and D-chiro-inositol, in order to better elucidate their physiological involvement inPCOS and potential therapeutic use, alone and in conjunction with assisted reproductive technologies, in the clinical treatment of women with PCOS.

Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials

The trial sequential analysis of insulin meta-analysis illustrates that the cumulative z-curve crossed the monitoring boundary, providing firm evidence of the intervention effect of MI in improving the metabolic profile of women with PCOS, concomitantly reducing their hyperandrogenism.

MYOINOSITOL: A REVIEW OF ITS USE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME

Treatment with MI improves the ovarian function, oocyte quality, metabolic and hormonal parameters in PCOS, and it has been shown to reduce the systolic and diastolic blood pressure.

Advances in Treatment Options for Polycystic Ovary Syndrome

An increasing level of therapeutic sophistication is reflected in ovarian stimulation protocols judiciously using gonadotropins, gonadotropic-releasing hormone antagonists, the procedure of ovarian drilling, and assisted reproductive technologies with in vitro oocyte maturation.

Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome

The administration of MI/D-chiro-inositol, in the physiological plasma ratio (i.e., 40:1) ensures better clinical results, such as the reduction of insulin resistance, androgens’ blood levels, cardiovascular risk and regularization of menstrual cycle with spontaneous ovulation.

Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols

Based on the published results, both MI and DCI represent potential valid therapeutic approaches for the treatment of insulin resistance and its associated metabolic and reproductive disorders, such as those occurring in women affected by PCOS.

Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature

Myo-inositol has proven to be a new treatment option for patients with PCOS and infertility and the achieved pregnancy rates are at least in an equivalent or even superior range than those reported using metformin as an insulin sensitizer.

Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials

During IVF, MI is effective in both PCOS and non-PCOS women in saving gonadotropins, but reduces efficiently SL only in PCOS women.

Inositol as putative integrative treatment for PCOS.

  • A. Genazzani
  • Biology, Medicine
    Reproductive biomedicine online
  • 2016
...

References

SHOWING 1-10 OF 49 REFERENCES

Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction

  • E. PapaleoV. Unfer A. Ferrari
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS, and did not cause multiple pregnancy.

Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial.

A beneficial effect of inositol in improving ovarian function in women with oligomenorrhea and polycystic ovaries is found and the inverse relationship between body mass of the patients and the efficacy of the treatment is found.

Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women

  • E. RaffoneP. RizzoV. Benedetto
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2010
Both metformin and MYO, can be considered as first line treatment for restoring normal menstrual cycles in most patients with PCOS, even if MYO treatment seems to be more effective than meetformin.

Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.

Data support a beneficial effect of myo-inositol in women with oligomenorrhea and polycystic ovaries in improving ovarian function and there was an inverse relationship between body mass and treatment efficacy.

Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.

Treatment of PCOS patients with Myo-inositol provided a decreasing of circulating insulin and serum total testosterone as well as an improvement in metabolic factors.

Insulin-lowering agents in the management of polycystic ovary syndrome.

In a high percentage of patients, treatment with metformin is followed by regularization of menstrual cycle, reduction in hyperandrogenism and in cardiovascular risk factors, and improvement in response to therapies for induction of ovulation.

Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia

The study demonstrates that metformin administration is more appropriate in hyperinsulinemic hyperandrogenic non-obese PCOS patients.

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.

D-chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride concentrations.

Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome

Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion and insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index.

Insulin Sensitizers for Polycystic Ovary Syndrome

The present review will address the rationale for the use of insulin-sensitizing drugs to treat both the short-term and long-term issues in PCOS and emphasize the importance of preventing the long- term risks associated with PCOS, if possible, when choosing a pharmacologic therapy.